MiMedx Group (NASDAQ:MDXG) Rating Reaffirmed
They currently have a $12.0 target on MiMedx Group (NASDAQ:MDXG). The target price by Canaccord Genuity would suggest a potential upside of 34.53% from the company’s close price. This has been released in analysts report on 18 December.
From a total of 7 analysts covering MiMedx Group (NASDAQ:MDXG) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $15 while the lowest target price is $10. The mean of all analyst targets is $12.14 with a 28.92% above today’s ($8.92) stock price. MiMedx Group was the topic of 4 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Needham upgraded shares on November 16 to “Strong Buy” rating.
The stock closed the day at $8.92 during the previous session. It is down 10.71% since May 15, 2015 and is downtrending. It has underperformed by 6.90% the S&P500.
The overall sentiment of institutions has decreased to 1.09 in Q2 2015. Its down 1.03, from 2.12 in 2015Q2. The ratio dived, as 24 institutions have sold all the shares of MiMedx Group Inc that they owned while 56 funds have taken shares off the table. 31 funds have purchased shares for the first time while 56 added to their positions. These institutions now hold 45.12 million shares or 12.07% less than the 51.32 million shares they owned in 2015Q2.
The Fund Oberweis Asset Management Inc currently is holding shares equating to 2.31% of its total portfolio in MiMedx Group Inc representing a total of 820,050 shares. Another fund,Millrace Asset Group Inc., is holding a total of 181,292 shares equating to 1.88% of their holdings. Additionally, Summit Capital Management Llc has a 358,650 share stake in MiMedx Group Inc which represents 1.69% of their total portfolio. The Fund, Summit Creek Advisors Llc, based out of Minnesota, has also built up a stake in the stock, which represents a total of 1.47% of their total portfolio. Finally Parsons Capital Management Inc Ri, a fund which is based in the state of Rhode Island reported a total holdings of 708,050 shares.
MiMedx Group, Inc. is an integrated developer, maker and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The company has a market cap of $882.60 million. The Company’s biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. It has 51.31 P/E ratio. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste.
According to Zacks Investment Research, “MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.”